Cargando…

BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

Dendritic cell (DC) vaccines show promising effects in cancer immunotherapy. However, their efficacy is affected by a number of factors, including (1) the quality of the DC vaccine and (2) tumor immune evasion. The recently characterized BDCA1+CD14+ immunosuppressive cells combine both aspects; thei...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Ee, Thomas J., Van Acker, Heleen H., van Oorschot, Tom G., Van Tendeloo, Viggo F., Smits, Evelien L., Bakdash, Ghaith, Schreibelt, Gerty, de Vries, I. Jolanda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161086/ https://www.ncbi.nlm.nih.gov/pubmed/30235890 http://dx.doi.org/10.3390/vaccines6030065

Ejemplares similares

CD56 in the Immune System: More Than a Marker for Cytotoxicity?
por: Van Acker, Heleen H., et al.
Publicado: (2017)

Enterovirus-Infected β-Cells Induce Distinct Response Patterns in BDCA1(+) and BDCA3(+) Human Dendritic Cells
por: Schulte, Barbara M., et al.
Publicado: (2015)

Metabolomic and lipidomic signatures associated with activation of human cDC1 (BDCA3(+)/CD141(+)) dendritic cells
por: Basit, Farhan, et al.
Publicado: (2021)

CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15
por: Van Acker, Heleen H., et al.
Publicado: (2019)

Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets
por: Sköld, Annette E., et al.
Publicado: (2015)

Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity
por: van Beek, Jasper J. P., et al.
Publicado: (2016)

Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion
por: Van Acker, Heleen H., et al.
Publicado: (2018)

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets
por: Sittig, Simone P., et al.
Publicado: (2016)

Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
por: Van Acker, Heleen H, et al.
Publicado: (2015)

Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity
por: Van den Bergh, Johan, et al.
Publicado: (2015)

Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
por: Van Acker, Heleen H., et al.
Publicado: (2016)

Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner
por: Anguille, Sébastien, et al.
Publicado: (2015)

Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential
por: Anguille, Sébastien, et al.
Publicado: (2012)

Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells
por: Sköld, Annette E., et al.
Publicado: (2018)

Correction: Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential
por: Anguille, Sébastien, et al.
Publicado: (2014)

Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation
por: Sittig, Simone P., et al.
Publicado: (2015)

Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection
por: Ouaguia, Laurissa, et al.
Publicado: (2019)

Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells
por: Van Acker, Heleen H., et al.
Publicado: (2017)

Sampling Site Matters When Counting Lymphocyte Subpopulations
por: Ogunjimi, Benson, et al.
Publicado: (2012)

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer
por: Bödder, Johanna, et al.
Publicado: (2021)

Characterization of BDCA1 and BDCA4 dendritic cell subsets in rheumatoid arthritis patients
por: Lebre, MC, et al.
Publicado: (2004)

Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC
por: Lion, Eva, et al.
Publicado: (2011)

Paramyxovirus Infection Regulates T Cell Responses by BDCA-1(+) and BDCA-3(+) Myeloid Dendritic Cells
por: Gupta, Meera R., et al.
Publicado: (2014)

Immunosuppression induced by immature dendritic cells is mediated by TGF-β/IL-10 double-positive CD4(+) regulatory T cells
por: Cools, N, et al.
Publicado: (2008)

The nature of activatory and tolerogenic dendritic cell-derived signal II
por: Bakdash, Ghaith, et al.
Publicado: (2013)

Innate Lymphoid Cells in Tumor Immunity
por: van Beek, Jasper J. P., et al.
Publicado: (2016)

Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy
por: Mathan, Till S.M., et al.
Publicado: (2017)

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
por: van Willigen, Wouter W., et al.
Publicado: (2018)

Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022)

New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia
por: Jordaens, Stephanie, et al.
Publicado: (2020)

Differential response of BDCA-1(+) and BDCA-3(+) myeloid dendritic cells to respiratory syncytial virus infection
por: Gupta, Meera R, et al.
Publicado: (2013)

BDCA1(+) cDC2s, BDCA2(+) pDCs and BDCA3(+) cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients
por: Sosa Cuevas, Eleonora, et al.
Publicado: (2020)

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
por: Wimmers, Florian, et al.
Publicado: (2014)

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
por: Versteven, Maarten, et al.
Publicado: (2018)

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
por: Van Acker, Heleen H., et al.
Publicado: (2019)

Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG
por: Wefers, Christina, et al.
Publicado: (2018)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

The Effect of Chronic Hepatitis B Virus Infection on BDCA3+ Dendritic Cell Frequency and Function
por: van der Aa, Evelyn, et al.
Publicado: (2016)

Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
por: de Bruijn, Sévérine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_85164pj8pgt27sf20cnv8692m1